Literature DB >> 24436776

A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.

Thomas M Braun1, Nan Jia1.   

Abstract

Entities:  

Year:  2013        PMID： 24436776      PMCID： PMC3891671          DOI： 10.1080/19466315.2013.767213

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN： 1946-6315            Impact factor:   1.452


× No keyword cloud information.
  15 in total

1.  Dose-finding with two agents in Phase I oncology trials.

Authors:  Peter F Thall; Randall E Millikan; Peter Mueller; Sang-Joon Lee
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

2.  Designs for single- or multiple-agent phase I trials.

Authors:  Mark R Conaway; Stephanie Dunbar; Shyamal D Peddada
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

3.  Two-dimensional dose finding in discrete dose space.

Authors:  Kai Wang; Anastasia Ivanova
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

4.  Sequential continual reassessment method for two-dimensional dose finding.

Authors:  Ying Yuan; Guosheng Yin
Journal:  Stat Med       Date:  2008-11-29       Impact factor: 2.373

5.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

6.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

7.  A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.

Authors:  Thomas M Braun; Shufang Wang
Journal:  Biometrics       Date:  2010-09       Impact factor: 2.571

8.  Some practical improvements in the continual reassessment method for phase I studies.

Authors:  S N Goodman; M L Zahurak; S Piantadosi
Journal:  Stat Med       Date:  1995-06-15       Impact factor: 2.373

9.  Practical modifications of the continual reassessment method for phase I cancer clinical trials.

Authors:  D Faries
Journal:  J Biopharm Stat       Date:  1994-07       Impact factor: 1.051

10.  Continual reassessment method for ordered groups.

Authors:  John O'Quigley; Xavier Paoletti
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571
View more
  10 in total

1.  Identifying a maximum tolerated contour in two-dimensional dose finding.

Authors:  Nolan A Wages
Journal:  Stat Med       Date:  2016-02-22       Impact factor: 2.373

2.  A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data.

Authors:  Graham M Wheeler; Michael J Sweeting; Adrian P Mander
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-11-22       Impact factor: 1.864

3.  A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.

Authors:  Akihiro Hirakawa; Nolan A Wages; Hiroyuki Sato; Shigeyuki Matsui
Journal:  Stat Med       Date:  2015-05-13       Impact factor: 2.373

4.  A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.

Authors:  Liangcai Zhang; Ying Yuan
Journal:  Stat Med       Date:  2016-08-31       Impact factor: 2.373

Review 5.  Practical designs for Phase I combination studies in oncology.

Authors:  Nolan A Wages; Anastasia Ivanova; Olga Marchenko
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

6.  A nonparametric Bayesian method for dose finding in drug combinations cancer trials.

Authors:  Zahra S Razaee; Galen Cook-Wiens; Mourad Tighiouart
Journal:  Stat Med       Date:  2022-01-25       Impact factor: 2.373

7.  Motivating sample sizes in adaptive Phase I trials via Bayesian posterior credible intervals.

Authors:  Thomas M Braun
Journal:  Biometrics       Date:  2018-03-13       Impact factor: 1.701

8.  A simulation-free approach to assessing the performance of the continual reassessment method.

Authors:  Thomas M Braun
Journal:  Stat Med       Date:  2020-09-16       Impact factor: 2.497

9.  A product of independent beta probabilities dose escalation design for dual-agent phase I trials.

Authors:  Adrian P Mander; Michael J Sweeting
Journal:  Stat Med       Date:  2015-01-29       Impact factor: 2.373

10.  On the coherence of model-based dose-finding designs for drug combination trials.

Authors:  Yeonhee Park; Suyu Liu
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.